Kymera to study role of IRAK4 in hidradenitis suppurativa, atopic dermatitis

Kymera Therapeutics has initiated a non-interventional trial evaluating IRAK4 expression in hidradenitis suppurativa and atopic dermatitis, according to a press release.

Orally administered IRAK4 degraders are being developed to treat toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven autoimmune and autoinflammatory diseases, the release said.

“The information from this study will further our understanding of the role of IRAK4 in the pathogenesis of HS as well as AD, another TLR/IL-1R-driven inflammatory skin disease, and set the stage for future interventional trials in these patient populations using our IRAK4 degraders,” Jared Gollob, MD, chief medical officer of Kymera, said in the release.

The trial will include up to 30 patients with HS and up to 10 patients with AD.